Professionals have the opportunity to alert their patients to an insurance policy that can fund licensed drugs that are difficult to obtain on the NHS.
The Western Provident Association (WPA) requires policy holders to pay an annual premium equal to their age in years which will then entitle them to £50,000 of treatment with licensed drugs, including Avastin for the treatment of age-related macular degeneration.
The policy is only available to the under-65s and cannot be started after a disease has been diagnosed, reported The Times (April 25).
WPA chief executive Julian Stainton said the policy was both a business opportunity and challenge to the NHS.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
